133 related articles for article (PubMed ID: 3098194)
1. Early and late changes in sulphydryl group and copper protein concentrations and activities during drug treatment with aurothiomalate and auranofin.
Rae KJ; Mackay CN; McNeil CJ; Brown DH; Smith WE; Lewis D; Capell HA
Ann Rheum Dis; 1986 Oct; 45(10):839-46. PubMed ID: 3098194
[TBL] [Abstract][Full Text] [Related]
2. A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.
Capell HA; Lewis D; Carey J
Ann Rheum Dis; 1986 Sep; 45(9):705-11. PubMed ID: 3094463
[TBL] [Abstract][Full Text] [Related]
3. A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate.
Hull RG; Morgan SH; Parke AL; Childs L; Goldman M; Hughes GR
Int J Clin Pharmacol Res; 1984; 4(6):395-401. PubMed ID: 6442711
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of the effects of auranofin and aurothiomalate on laboratory and clinical indicators in patients with rheumatoid arthritis].
Vlak T; Stambuk B
Reumatizam; 1998; 46(1):7-19. PubMed ID: 9921004
[TBL] [Abstract][Full Text] [Related]
5. Erythrocyte membrane gold levels after treatment with auranofin and sodium aurothiomalate.
Iqbal MS; Saeed M; Taqi SG
Biol Trace Elem Res; 2008; 126(1-3):56-64. PubMed ID: 18649049
[TBL] [Abstract][Full Text] [Related]
6. Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two-year open randomized study.
Harth M; Davis P; Thompson JM; Menard H; Beaudet F
Scand J Rheumatol; 1987; 16(3):177-84. PubMed ID: 3110944
[TBL] [Abstract][Full Text] [Related]
7. Gold levels produced by treatment with auranofin and sodium aurothiomalate.
Lewis D; Capell HA; McNeil CJ; Iqbal MS; Brown DH; Smith WE
Ann Rheum Dis; 1983 Oct; 42(5):566-70. PubMed ID: 6414387
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous lymphocyte activity in rheumatoid arthritis in a longitudinal study in relation to gold therapy.
Froebel KS; Lewis D; Dickson R; Sturrock RD
Clin Rheumatol; 1985 Sep; 4(3):301-7. PubMed ID: 3933897
[TBL] [Abstract][Full Text] [Related]
9. A three year comparative study of auranofin and gold sodium thiomalate in rheumatoid arthritis.
Rau R; Schattenkirchner M; Muller-Fassbender H; Kaik B; Zeidler H; Missler B
Clin Rheumatol; 1990 Dec; 9(4):461-74. PubMed ID: 2128475
[TBL] [Abstract][Full Text] [Related]
10. [Well controlled comparative study in early rheumatoid arthritis with gold sodium thiomalate vs. auranofin].
Yamamoto S; Mitomo N; Saito T; Nishioka K; Inoue K; Uchida S; Ohata N; Murasawa A; Suzuki A; Mitsui T
Ryumachi; 1990 Feb; 30(1):26-44. PubMed ID: 2116042
[TBL] [Abstract][Full Text] [Related]
11. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study.
Schattenkirchner M; Kaik B; Muller-Fassbender H; Rau R; Zeidler H
J Rheumatol Suppl; 1982; 8():184-9. PubMed ID: 6813483
[TBL] [Abstract][Full Text] [Related]
12. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin.
Menard HA; Beaudet F; Davis P; Harth M; Percy JS; Russell AS; Thompson JM
J Rheumatol Suppl; 1982; 8():179-83. PubMed ID: 6813482
[TBL] [Abstract][Full Text] [Related]
13. Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy.
Crilly A; Madhok R; Watson J; Capell HA; Sturrock RD
Br J Rheumatol; 1994 Sep; 33(9):821-5. PubMed ID: 7915945
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs.
Crilly A; Madhok R; Watson J; Capell HA
Ann Rheum Dis; 1993 Jan; 52(1):58-60. PubMed ID: 8093995
[TBL] [Abstract][Full Text] [Related]
15. Serum copper and erythrocyte superoxide dismutase in rheumatoid arthritis.
Banford JC; Brown DH; Hazelton RA; McNeil CJ; Sturrock RD; Smith WE
Ann Rheum Dis; 1982 Oct; 41(5):458-62. PubMed ID: 7125714
[TBL] [Abstract][Full Text] [Related]
16. Evidence for carbimazole as an antioxidant?
Wilson R; Buchanan L; Fraser WD; Jenkins C; Smith WE; Reglinski J; Thomson JA; McKillop JH
Autoimmunity; 1998; 27(3):149-53. PubMed ID: 9609132
[TBL] [Abstract][Full Text] [Related]
17. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.
Chaffman M; Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1984 May; 27(5):378-424. PubMed ID: 6426923
[TBL] [Abstract][Full Text] [Related]
18. One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo.
Williams HJ; Dahl SL; Ward JR; Karg M; Willkens RF; Meenan RF; Altz-Smith M; Clegg DO; Mikkelsen WM; Kay DR
Arthritis Rheum; 1988 Jan; 31(1):9-14. PubMed ID: 3125841
[TBL] [Abstract][Full Text] [Related]
19. Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine.
Pullar T; Zoma A; Capell HA; Khan MF; Brown DH; Smith WE
Br J Rheumatol; 1987 Jun; 26(3):202-6. PubMed ID: 2884009
[TBL] [Abstract][Full Text] [Related]
20. [Possible mechanism of action of drugs in the basic therapy of rheumatoid arthritis: effect on platelet aggregation].
Fioravanti A; Lolatte V; Giordano N; Frati E; Castagna ML; Morozzi G; Lalumera M; Marcolongo R
Boll Soc Ital Biol Sper; 1984 May; 60(5):1051-6. PubMed ID: 6432005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
